DUBLIN--(BUSINESS WIRE)--The "Global Central Nervous System Biomarkers Market - Growth, Trends and Forecasts (2017 - 2022)" report has been added to Research and Markets' offering.
The CNS disorders have been increasing and so is the need for treatments. Biomarkers are medical signs or objective indications of a medical state observed from outside the patient, measured accurately and reproducibly. The CNS biomarkers are used to detect and identify the state of a CNS disease, like the Parkinson's disease.
The high investment in proteomics and genomics research and the need for cost-efficient solutions to treat CNS disorders are the major factors accelerating the market growth. However, there are certain factors that are hindering the market growth, which include high cost of CNS biomarker test & diagnostics and certain issues related to regulatory and reimbursement systems.
The global market is segmented based on application, end-users and geography. The North American market for CNS biomarkers is expected to hold the largest share, globally, due to the rapid use of various cardiac biomarkers combinations.
- Development in Proteomics and Genomics has led to Discovery of Novel Biomarkers.
- Funding from Government and Private Players to boost CNS Biomarker Market
- High Cost of CNS Biomarker Test and Diagnostics
- Issues Related to Regulatory and Reimbursement Systems
- Thermo Fisher Scientific
- Merck & Co.
- Abastar Mdx Inc.
- Abiant Inc.
- Avacta Group Plc.
Key Topics Covered:
2. Executive Summary
3. Key Inferences
4. Market Overview
5. Drivers, Restraints, Opportunities & Challenges Analysis (DROC)
6. Types of CNS Biomarker
7. Market Segmentation
8. Competitive Landscape
9. Company Profiles
10. Future Market Scenario
For more information about this report visit https://www.researchandmarkets.com/research/gqq4m4/global_central